Failure to mention fixed-dose drug combinations in the ATS/CDC/IDSA tuberculosis control statement [3]

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 6, 2006, Pages 684-

  Moulding, Thomas ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

DIRECTLY OBSERVED THERAPY; HOSPITAL PHYSICIAN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; LETTER; MEDICAL SOCIETY; MEDICATION ERROR; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; COMPARATIVE STUDY; DRUG COMBINATION; EPIDEMIC; NOTE; RISK FACTOR; UNITED STATES; PHYSICIAN; PUBLIC HEALTH; TREATMENT FAILURE;

ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; DRUG COMBINATIONS; HUMANS; RISK FACTORS; SOCIETIES, MEDICAL; TUBERCULOSIS; UNITED STATES;

EID: 33644837693     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/ajrccm.173.6.684     Document Type: Letter

References (4)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-1227.
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
3. Moulding TS, Le HQ, Rickleen D, Davidson P. Preventing drug resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 2004;8:743-748.
4. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2004. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.